Gilead

FDA approves Gilead's Stribild, four-in-one HIV drug

Wednesday, August 29, 2012 10:19 AM

The FDA has approved Stribild, a complete once-daily single tablet regimen, for the treatment of HIV-1 infection in treatment-naïve adults, according to Gilead Sciences, the Foster City, Calif.-based biopharmaceutical company that developed the drug.

More... »

Gilead collaborates with Indian partners to reduce costs, improve availability of antiretroviral therapy

Thursday, August 2, 2012 02:44 PM

Pharmaceutical companies Gilead Sciences, Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab have entered into agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine (FTC) in developing countries, including single tablet regimens containing emtricitabine and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

More... »

FDA approves Viread for children with HIV-I

Friday, January 20, 2012 03:48 PM

The FDA has approved Gilead Sciences’ Viread (tenofovir disoproxil fumarate) in combination with other antiretroviral agents for the treatment of HIV-I infection in pediatric patients ages 2 to 12.

More... »

Gilead Sciences acquires Pharmasset, looks to duplicate its HIV success in hepatitis C

Monday, November 28, 2011 08:02 AM

Consolidation among drug sponsors continues. 

More... »

Gilead to acquire Pharmasset for $11 billion

Monday, November 21, 2011 03:36 PM

Gilead Sciences and Pharmasset have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction, which values Pharmasset at approximately $11 billion, was unanimously approved by Pharmasset's board of directors. Gilead plans to finance the transaction with cash on hand, bank debt and senior unsecured notes. The company expects the transaction, when completed, to be dilutive to Gilead's earnings through 2014 and accretive in 2015 and beyond. Further guidance will be provided when the transaction closes, which is expected to be in the first quarter of 2012.

More... »

Gilead submits NDA for HIV regimen

Friday, October 28, 2011 01:43 PM

Gilead Sciences has submitted a New Drug Application (NDA) to the FDA for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. If approved, the Quad would be the only once-daily, single-tablet regimen containing an integrase inhibitor.

More... »

Bristol-Myers, Gilead ink licensing agreement for HIV medicines

Thursday, October 27, 2011 12:41 PM

Bristol-Myers Squibb and Gilead Sciences have signed a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing. Gilead is currently studying atazanavir and cobicistat in phase II and III studies in HIV-1 treatment-naive patients.

More... »

Gilead, GlobeImmune collaborate

Tuesday, October 25, 2011 11:46 AM

Gilead Sciences and GlobeImmune have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of therapeutic vaccine products for use in conjunction with Viread (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.

More... »

Redwood Bioscience names executive chairman

Tuesday, October 4, 2011 10:53 AM

Redwood Bioscience has named Peter Van Vlasselaer, PhD, executive chairman to Redwood's board of directors.  In this role, Vlasselaer will be actively guiding Redwood on drug and platform development as well as corporate strategy.  

More... »

Gilead to allow generic AIDS drugs through Medicines Patent Pool

Wednesday, July 13, 2011 10:46 AM

Gilead Sciences will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, according to the Associated Press.

More... »